452 related articles for article (PubMed ID: 36946186)
1. Targeted therapies in advanced biliary tract cancers-a narrative review.
LaPelusa M; Heumann T; Goff L; Agarwal R
Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
[TBL] [Abstract][Full Text] [Related]
2. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
Lamarca A; Barriuso J; McNamara MG; Valle JW
J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatment of advanced or recurrent biliary tract cancer.
Zhang W; Zhou H; Wang Y; Zhang Z; Cao G; Song T; Zhang T; Li Q
Biosci Trends; 2020 Nov; 14(5):328-341. PubMed ID: 32830166
[TBL] [Abstract][Full Text] [Related]
6. Current and emerging immunotherapeutic approaches for biliary tract cancers.
Yuan ZG; Zeng TM; Tao CJ
Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
[TBL] [Abstract][Full Text] [Related]
7. Current and emerging therapies for advanced biliary tract cancers.
Kam AE; Masood A; Shroff RT
Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):956-969. PubMed ID: 34626563
[TBL] [Abstract][Full Text] [Related]
8. How I treat biliary tract cancer.
Lamarca A; Edeline J; Goyal L
ESMO Open; 2022 Feb; 7(1):100378. PubMed ID: 35032765
[TBL] [Abstract][Full Text] [Related]
9. Molecular-driven treatment for biliary tract cancer: the promising turning point.
Persano M; Puzzoni M; Ziranu P; Pusceddu V; Lai E; Pretta A; Donisi C; Pinna G; Spanu D; Cimbro E; Parrino A; Liscia N; Mariani S; Dubois M; Migliari M; Scartozzi M
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1253-1264. PubMed ID: 34551663
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for biliary tract cancers.
Faris JE; Zhu AX
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):326-36. PubMed ID: 22318523
[TBL] [Abstract][Full Text] [Related]
11. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
Rizzo A; Federico AD; Ricci AD; Frega G; Palloni A; Pagani R; Tavolari S; Marco MD; Brandi G
Cancer Control; 2020; 27(1):1073274820983013. PubMed ID: 33356500
[TBL] [Abstract][Full Text] [Related]
12. The state of therapy modalities in clinic for biliary tract cancer.
Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
[TBL] [Abstract][Full Text] [Related]
13. Current options and future directions of systemic therapy for advanced biliary tract cancer.
Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
[TBL] [Abstract][Full Text] [Related]
14. Biliary cancer: Utility of next-generation sequencing for clinical management.
Javle M; Bekaii-Saab T; Jain A; Wang Y; Kelley RK; Wang K; Kang HC; Catenacci D; Ali S; Krishnan S; Ahn D; Bocobo AG; Zuo M; Kaseb A; Miller V; Stephens PJ; Meric-Bernstam F; Shroff R; Ross J
Cancer; 2016 Dec; 122(24):3838-3847. PubMed ID: 27622582
[TBL] [Abstract][Full Text] [Related]
15. A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
Aimar G; Paratore C; Zichi C; Marino D; Sperti E; Caglio A; Gamba T; De Vita F; Di Maio M
Explor Target Antitumor Ther; 2021; 2(5):448-464. PubMed ID: 36045702
[TBL] [Abstract][Full Text] [Related]
16. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
Bath NM; Pawlik TM
Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
[TBL] [Abstract][Full Text] [Related]
18. Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
[No Abstract] [Full Text] [Related]
19. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.
Ten Haaft BH; Pedregal M; Prato J; Klümpen HJ; Moreno V; Lamarca A
Eur J Cancer; 2024 Mar; 199():113564. PubMed ID: 38266541
[TBL] [Abstract][Full Text] [Related]
20. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]